GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $3,951 | $1,079 | $5,672 | $8,968 |
| Short-Term Investments | $0 | $12,893 | $10,836 | $23,011 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $281 | $84 | $54 | $190 |
| Total Curr. Assets | $4,232 | $14,056 | $16,562 | $32,169 |
| Property Plant & Equip (Net) | $0 | $53 | $165 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $9 | $0 |
| Total NC Assets | $0 | $53 | $174 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $4,232 | $14,109 | $16,736 | $32,169 |
| Liabilities | – | – | – | – |
| Payables | $3,853 | $4,328 | $3,140 | $8,189 |
| Short-Term Debt | $0 | $58 | $110 | $31 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $1,901 |
| Other Curr. Liab. | $2,049 | $2,247 | $1,688 | $138 |
| Total Curr. Liab. | $5,902 | $6,633 | $4,938 | $10,259 |
| LT Debt | $0 | $0 | $64 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $64 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $58 | $174 | $0 |
| Total Liabilities | $5,902 | $6,633 | $5,002 | $10,259 |
| Equity | – | – | – | – |
| Pref Stock | $1 | $1 | $1 | $1 |
| Common Stock | $2 | $1 | $33 | $1,145 |
| Retained Earnings | -$695,227 | -$682,065 | -$674,468 | -$653,584 |
| AOCI | $0 | $0 | $0 | $1,113 |
| Other Equity | $693,554 | $689,539 | $686,168 | $673,235 |
| Total Equity | -$1,670 | $7,476 | $11,734 | $21,910 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $4,232 | $14,109 | $16,736 | $32,169 |
| Net Debt | -$3,951 | -$1,021 | -$5,498 | -$8,937 |